1. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
- Author
-
Mayer-Hamblett, Nicole, Ratjen, Felix, Russell, Renee, Donaldson, Scott H, Riekert, Kristin A, Sawicki, Gregory S, Odem-Davis, Katherine, Young, Julia K, Rosenbluth, Daniel, Taylor-Cousar, Jennifer L, Goss, Christopher H, Retsch-Bogart, George, Clancy, John Paul, Genatossio, Alan, O'Sullivan, Brian P, Berlinski, Ariel, Millard, Susan L, Omlor, Gregory, Wyatt, Colby A, Moffett, Kathryn, Nichols, David P, Gifford, Alex H, Kloster, Margaret, Weaver, Katie, Chapdu, Claire, Xie, Jing, Skalland, Michelle, Romasco, Melita, Heltshe, Sonya, Simon, Noah, VanDalfsen, Jill, Mead, Anna, Buckingham, Rachael, Seidel, Kathy, Midamba, Nikita, Couture, Laurel, Case, Brooke Zappone, Au, Wendy, Rockers, Elsie, Cooke, Diane, Olander, Amber, Bondick, Irene, Johnson, Miya, VanHousen, Lisya, Nicholson, Boris, Omlor, Gregory, Parrish, Michelle, Roberts, Dion, Head, Jillian, Carey, Jessica, Caverly, Lindsay, Dangerfield, Joy, Linnemann, Rachel, Fullmer, Jason, Roman, Chelsea, Mogayzel, Peter, Reyes, Deanne, Harmala, Amy, Lysinger, Jerimiah, Bergeron, Jonathan, Virella-Lowell, Isabel, Brown, Perry, Godusevic, Lejla, Casey, Alicia, Paquette, Lauren, Lahiri, Thomas, Sweet, Julie, Donaldson, Scott, Harris, Joshua, Parnell, Shelia, Szentpetery, Sylvia, Froh, Deborah, Tharrington, Erica, Jain, Manu, Nelson, Rachel, Kadon, Sharon, McPhail, Gary, McBennett, Kimberly, Rone, Tia, Dasenbrook, Elliott, Weaver, Dave, Johnson, Terri, McCoy, Karen, Jain, Raksha, Mcleod, Maria, Klosterman, Mary, Sharma, Preeti, Jones, Amy, Mueller, Gary, Janney, Rachel, Taylor-Cousar, Jennifer, Cross, Mary, Hoppe, Jordana, Cahill, James, Mukadam, Zubin, Finto, Jill, Schultz, Karen, Villalta, Silvia Delgado, Smith, Alexa, Millard, Susan, Symington, Thomas, Graff, Gavin, Kitch, Diane, Sanders, Don, Thompson, Misty, Pena, Tahuanty, Teresi, Mary, Gafford, Jennifer, Schaeffer, David, Mermis, Joel, Scott, Lawrence, Escobar, Hugo, Williams, Kristen, Dorman, Dana, O'Sullivan, Brian, Bethay, Ryan, Danov, Zoran, Berlinski, Ariel, Turbeville, Kat, Johannes, Jimmy, Rodriguez, Angelica, Marra, Bridget, Zanni, Robert, Morton, Ronald, Simeon, Terri, Braun, Andrew, Dondlinger, Nicole, Biller, Julie, Hubertz, Erin, Antos, Nicholas, Roth, Laura, Billings, Joanne, Larson, Catherine, Balaji, Priya, McNamara, John, Clark, Tammy, Moffett, Kathryn, Griffith, Rebecca, Martinez, Nancy, Hussain, Sabiha, Malveaux, Halina, Egan, Marie, Guzman, Catalina, DeCelie-Germana, Joan, Galvin, Susan, Savant, Adrienne, Falgout, Nicole, Walker, Patricia, Demarco, Teresa, DiMango, Emily, Ycaza, Maria, Ballo, Julie, Tirakitsoontorn, Pornchai, Layish, Daniel, Serr, Desiree, Livingston, Floyd, Wooldridge, Sherry, Milla, Carlos, Spano, Jacquelyn, Davis, Rebecca, Elidemir, Okan, Chittivelu, Subramanyam, Scott, Ashley, Alam, Sarah, Dorgan, Daniel, Butoryak, Matt, Weiner, Daniel, Renna, Harmony, Wyatt, Colby, Klein, Brendan, Stone, Anne, Lessard, Meg, Schechter, Michael S., Johnson, Barbara, Scofield, Steven, Liou, Theodore, Vroom, Jane, Akong, Kathryn, Gil, Marissa, Betancourt, Legna, Singer, Jonathan, Ly, Ngoc, Moreno, Courtney, Aitken, Moira, Gambol, Teresa, Genatossio, Alan, Gibson, Ronald, Lambert, Allison, Milton, Joan, Rosenbluth, Daniel, Smith, Sarah, Green, Deanna, Hodge, Diana, Fortner, Christopher, Forell, Mary, Karlnoski, Rachel, Patel, Kapil, Daines, Cori, Ryan, Elizabeth, Amaro-Galvez, Rodolfo, Dohanich, Elizabeth, Lennox, Alison, Messer, Zachary, Hanes, Holly, Powell, Kay, and Polineni, Deepika
- Abstract
Reducing treatment burden is a priority for people with cystic fibrosis, whose health has benefited from using new modulators that substantially increase CFTR protein function. The SIMPLIFY study aimed to assess the effects of discontinuing nebulised hypertonic saline or dornase alfa in individuals using the CFTR modulator elexacaftor plus tezacaftor plus ivacaftor (ETI).
- Published
- 2023
- Full Text
- View/download PDF